Key Takeaways
- €5 million Series A closed by Pisa-based Wearable Robotics, led by CDP Venture Capital with five co-investors
- Flagship product ALEX RS, a bilateral upper-limb exoskeleton covering 92% of natural arm range of motion, already deployed in 50+ installations across 20+ countries
- Funds earmarked for North American market entest, regulatory approvals, product portfolio expansion, and distribution network scale-up
- Company holds a family of 8 proprietary patents and serves an estimated global patient pool of 200 million people requireding neuromotor rehabilitation
Quick Recap
Italian rehabilitation robotics startup Wearable Robotics has officially closed a €5 million Series A funding round to accelerate global expansion and advance its exoskeleton product portfolio, according to an announcement first shared by EU Startups on April 2, 2026.
The round was led by CDP Venture Capital through its Accelerators Fund, with participation from MITO Technology, LIFTT, SIMEST, RoboIT, and the Toscana Next co-investment fund. The Pisa-based company, a spin-off of the renowned Scuola Superiore Sant’Anna, is one of Europe’s most clinically validated rehabilitation robotics developers.
Deal Insights
The funding syndicate behind this round is notably diverse, blconcludeing public-backed capital, regional development funds, and deep-tech specialists. CDP Venture Capital led via the Accelerators Fund while SIMEST participated applying resources from Italy’s Ministest of Foreign Affairs and International Cooperation under the F.394/81 fund, which is specifically designed to support Italian companies expanding internationally.
RoboIT, the National Technology Transfer Hub for Robotics and Industrial Automation, also joined the round, reflecting a coordinated Italian public-private push behind the sector. The Toscana Next co-investment fund, backed by Tuscan banking foundations including Fondazione CR Firenze, Fondazione Cassa di Risparmio di Lucca, Fondazione Caript, and Fondazione Monte dei Paschi di Siena, rounds out the investor base.
The capital has specific strategic allocations. Wearable Robotics plans to utilize the €5 million to complete its product portfolio, advance regulatory compliance in tarreceive markets, expand sales channels internationally with a particular focus on North America, and optimize production capacity. The company’s commercial anchor is ALEX RS, a bilateral neuromotor rehabilitation device for the upper limb that integrates augmented and virtual reality therapy modes.
With five degrees of freedom (four active, one passive), the device covers approximately 92% of the natural human arm workspace, enabling robotic assistance during full spatial shiftment. Over 50 units are already installed across more than 20 countries. CEO Lucia Lencioni stated: “The completion of this funding round marks a crucial step in our development. We are laying the foundations for sustainable and scalable growth, whilst investing in product innovation, regulatory compliance and commercial development.
Massimiliano Granieri, managing director of MITO Technology, added: “This investment will support the scale-up phase and strengthen Wearable Robotics’ market position, generating lasting value for investors and stakeholders.” LIFTT’s Marco Parlani, who has backed the company since 2023, confirmed continued commitment, calling the team and technology “leaders in a high-potential market such as that of rehabilitation robotics.”
Beyond medical applications, Wearable Robotics operates a dual-division structure. NEXUM Medical focutilizes on upper limb rehabilitation integrating AR/VR, while NEXUM Industest develops exoskeletons to reduce worker fatigue and prevent musculoskeletal injuries in manual handling environments. This dual focus gives the company exposure to both the healthcare and industrial segments of the exoskeleton market.
Funding Round Drives Strategic Momentum
The timing of this raise is far from coincidental. The global wearable robots and exoskeletons market is valued at approximately USD 6.83 billion in 2026 and is projected to reach USD 24.28 billion by 2031, representing a CAGR of nearly 29%. Within the narrower medical rehabilitation robotics segment, the market is forecast to grow from USD 0.29 billion in 2024 to USD 1.33 billion by 2035 at a 15% CAGR.
This growth is being accelerated by aging global populations, rising stroke incidence, insurance reimbursement approvals for neuromotor devices in North America and Europe, and the rapid decline in costs of lightweight actuators. On the regulatory front, North America is becoming an increasingly attractive destination for rehabilitation robotics companies.
The Centers for Medicare & Medicaid Services (CMS) in the United States approved an approximately USD 91,000 reimbursement for personal exoskeleton devices in 2024, a landmark decision that broadened the addressable market substantially. For Wearable Robotics, tarreceiveing North America with SIMEST’s internationalization funding and completing FDA regulatory pathways is now a logical next shift given its existing clinical track record across 20 countries.
European robotics investment also hit a record in 2025, with capital flowing into the sector surging to €1.45 billion, more than doubling the prior year’s total and with deal volume rising 30%. Wearable Robotics’ Series A fits neatly into this broader continental trconclude of supporting hardware-first, clinically validated robotics companies over software-only plays. The company’s eight proprietary patents covering kinematics, sensors, actuation systems, and exoskeleton design provide meaningful defensive IP and reduce the commoditization risk that plagues younger hardware startups without protected core architectures.
The patient opportunity is also significant. According to Wearable Robotics’ own estimates, approximately 200 million patients globally require neuromotor rehabilitation following stroke, traumatic brain injury, and spinal cord injury. Even capturing a fraction of that base across new geographies would represent a step-modify in the company’s commercial footprint.
Competitive Landscape
Wearable Robotics operates in a specialized but growing field with several direct and emerging competitors at comparable scale and clinical focus. The two most relevant direct competitors for the upper-limb neuromotor rehabilitation niche are Fourier Rehab (formerly Fourier Ininformigence) and BIONIK Laboratories.
| Feature / Metric | Wearable Robotics (ALEX RS) | Fourier Rehab (ArmMotus EMU) | BIONIK Laboratories (InMotion ARM) |
| Founded | 2014 (Sant’Anna spin-off, Italy) | 2015, rebranded 2024 (Shanghai, China) | MIT-derived, Toronto & Boston |
| Flagship Upper Limb Device | ALEX RS — bilateral exoskeleton, 5 DoF | ArmMotus EMU – cable-driven 3D exoskeleton | InMotion ARM/HAND — robotic arm |
| Arm Range Coverage | 92% of natural arm workspace | Full 3D workspace via cable-driven parallel structure | Shoulder protraction/retraction, flexion/extension, abduction/adduction |
| AR/VR Integration | Yes – integrated AR/VR therapy modes | Yes – immersive game-based therapy with VR option (ExoMotus M4+VR) | AI + data analysis; gamified but limited VR |
| Clinical Deployments | 50+ installations, 20+ countries | 2,000+ institutions, 40+ countries | 20+ countries |
| Patents / IP | 8 proprietary patents (kinematics, sensors, actuation) | Not publicly disclosed | MIT-derived IP foundation |
| Funding Stage | Series A – €5 million (April 2026) | Revenue ~USD 29 million (2024) | Publicly traded OTCQB (BNKL) |
| Industrial Exoskeleton Arm | Yes – NEXUM Industest division | Yes – ExoMotus line | No – medical-only focus |
| North America Strategy | Planned entest with this round | Expanding via distributor network | Established presence (U.S. VA hospitals) |
Strategic Analysis
Wearable Robotics leads in clinically validated European IP depth and bilateral upper-limb specificity, with its 92% arm workspace coverage and 8-patent family giving it a differentiated hardware moat at a comparable commercial stage.
Fourier Rehab, however, commands a scale advantage with 40+ countest deployments and deeper AI-cloud integration, creating it the stronger choice for large hospital networks seeking full rehabilitation ecosystem solutions.
BIONIK’s InMotion ARM has the longest clinical trial record (150+ indepconcludeent studies involving 1,700+ patients), but as a listed microcap, it faces capital constraints that limit its growth velocity relative to the newly funded Italian challenger.
Bayelsa Watch’s Takeaway
In my view, this is a bullish signal for European deep-tech medtech, and not just becautilize €5 million modifyd hands. What creates this raise genuinely interesting is the architecture of the investor group. When you see CDP Venture Capital, SIMEST (backed by the Ministest of Foreign Affairs), RoboIT, and regional Tuscan banking foundations all writing checks into the same Series A, that is a coordinated bet from institutional Italy on a company it is treating as a national-level asset in global medtech.
I generally prefer founders who come out of applied research institutions rather than pure product shops, and Lucia Lencioni building this out of Sant’Anna is exactly that profile. I consider the North American push is the real story here. The CMS reimbursement approval for personal exoskeletons modifys the commercial calculus entirely for any rehabilitation robotics company sitting outside the U.S. with a proven product.
ALEX RS covering 92% of natural arm workspace and holding eight patents is not a prototype story. This is a clinically validated system now going after one of the most well-reimbursed healthcare markets in the world. The competitive challenge is real. Fourier Rehab serving 2,000+ institutions across 40 countries is a formidable benchmark, and BIONIK has decades of MIT-derived clinical data behind it.
Leave a Reply